Gene therapy approaches in the non-human primate model of Parkinson’s disease

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of neural transmission

• Publication date

  2018-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00702-017-1681-3PMID 28130586
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adeno-Associated Viral Vectors Serotype 8 for Cell-Specific Delivery of Therapeutic Genes in the Central Nervous System

  2017cited by this paper
• Sustained Gq-Protein Signaling Disrupts Striatal Circuits via JNK

  2016cited by this paper
• Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis.

  2016cited by this paper
• In Vivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis.

  2016cited by this paper
• DREADDs for Neuroscientists.

  2016cited by this paper
• Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications.

  2016cited by this paper
• How can rAAV‐α‐synuclein and the fibril α‐synuclein models advance our understanding of Parkinson's disease?

  2016cited by this paper
• In Vivo Reprogramming for CNS Repair: Regenerating Neurons from Endogenous Glial Cells.

  2016cited by this paper
• The relationship between glucocerebrosidase mutations and Parkinson disease

  2016cited by this paper
• Parkinson's disease: acid‐glucocerebrosidase activity and alpha‐synuclein clearance

  2016cited by this paper
• Neuroanatomy goes viral!

  2015cited by this paper
• Chemogenetic disconnection of monkey orbitofrontal and rhinal cortex reversibly disrupts reward value

  2015cited by this paper
• Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain

  2015cited by this paper
• Double Virus Vector Infection to the Prefrontal Network of the Macaque Brain

  2015cited by this paper
• Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies.

  2015cited by this paper
• DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility.

  2015cited by this paper
• Viral vector delivery of neurotrophic factors for Parkinson's disease therapy

  2015cited by this paper
• Increased oligomerization and phosphorylation of α-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains.

  2015cited by this paper
• Gq-DREADD Selectively Initiates Glial Glutamate Release and Inhibits Cue-induced Cocaine Seeking.

  2015cited by this paper
• Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.

  2015cited by this paper
• SOX2 Reprograms Resident Astrocytes into Neural Progenitors in the Adult Brain

  2015cited by this paper
• Adeno-Associated Virus Vectors and Neurological Gene Therapy

  2015cited by this paper
• Serotype-dependent transduction efficiencies of recombinant adeno-associated viral vectors in monkey neocortex

  2015cited by this paper
• The neostriatum: two entities, one structure?

  2015cited by this paper
• In Vivo Reprogramming of Striatal NG2 Glia into Functional Neurons that Integrate into Local Host Circuitry

  2015cited by this paper
• Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex.

  2015cited by this paper
• Gene delivery targeted to oligodendrocytes using a lentiviral vector

  2014cited by this paper
• Remote control of induced dopaminergic neurons in parkinsonian rats.

  2014cited by this paper
• Combined Use of the Canine Adenovirus-2 and DREADD-Technology to Activate Specific Neural Pathways In Vivo

  2014cited by this paper
• Ammonia as a case study for the spontaneous ionization of a simple hydrogen-bonded compound

  2014cited by this paper
• Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

  2014cited by this paper
• In vivo conversion of astrocytes to neurons in the injured adult spinal cord

  2014cited by this paper
• Skeletal Muscle Characterization of Japanese Quail Line Selectively Bred for Lower Body Weight as an Avian Model of Delayed Muscle Growth with Hypoplasia

  2014cited by this paper
• Designer receptor manipulations reveal a role of the locus coeruleus noradrenergic system in isoflurane general anesthesia

  2014cited by this paper
• Biology of adeno-associated viral vectors in the central nervous system

  2014cited by this paper
• Improved transduction efficiency of a lentiviral vector for neuron-specific retrograde gene transfer by optimizing the junction of fusion envelope glycoprotein.

  2014cited by this paper
• Whole-brain circuit dissection in free-moving animals reveals cell-specific mesocorticolimbic networks.

  2013cited by this paper
• Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain

  2013cited by this paper
• A Gαs DREADD Mouse for Selective Modulation of cAMP Production in Striatopallidal Neurons

  2013cited by this paper
• Glial Promoter Selectivity following AAV-Delivery to the Immature Brain

  2013cited by this paper
• Vectors for Highly Efficient and Neuron-Specific Retrograde Gene Transfer for Gene Therapy of Neurological Diseases

  2013cited by this paper
• Direct-Pathway Striatal Neurons Regulate the Retention of Decision-Making Strategies

  2013cited by this paper
• Dissecting circuit mechanisms by genetic manipulation of specific neural pathways

  2013cited by this paper
• Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease

  2012cited by this paper
• Genetics of Parkinson's disease.

  2012cited by this paper
• Functional neuroanatomy of the basal ganglia.

  2012cited by this paper
• Safety and Tolerability of Magnetic Resonance Imaging-Guided Convection-Enhanced Delivery of AAV2-hAADC with a Novel Delivery Platform in Nonhuman Primate Striatum

  2012cited by this paper
• AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth.

  2012cited by this paper
• Immunotoxin-Mediated Tract Targeting in the Primate Brain: Selective Elimination of the Cortico-Subthalamic “Hyperdirect” Pathway

  2012cited by this paper
• Living on the edge with too many mouths to feed: Why dopamine neurons die

  2012cited by this paper
• Heart repair by reprogramming non-myocytes with cardiac transcription factors

  2012cited by this paper
• The link between the GBA gene and parkinsonism.

  2012cited by this paper
• Dopaminergic pathway reconstruction by Akt/Rheb‐induced axon regeneration

  2011cited by this paper
• Abstract 10466: In Vivo Reprogramming of Murine Cardiac Fibroblasts into Induced Cardiomyocytes

  2011cited by this paper
• Lentiviral-Mediated Gene Transfer to the Sheep Brain: Implications for Gene Therapy in Batten Disease

  2011cited by this paper
• A Lentiviral Strategy for Highly Efficient Retrograde Gene Transfer by Pseudotyping with Fusion Envelope Glycoprotein

  2011cited by this paper
• Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease.

  2011cited by this paper
• Optimizing Promoters for Recombinant Adeno-Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-Complementary Vectors

  2011cited by this paper
• Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice.

  2011cited by this paper
• Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains

  2011cited by this paper
• Neuron-Specific Gene Transfer Through Retrograde Transport of Lentiviral Vector Pseudotyped with a Novel Type of Fusion Envelope Glycoprotein

  2011cited by this paper
• Production, purification and characterization of adeno-associated vectors.

  2010cited by this paper
• Regeneration of the MPTP-Lesioned Dopaminergic System after Convection-Enhanced Delivery of AAV2-GDNF

  2010cited by this paper
• A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease.

  2010cited by this paper
• Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

  2010cited by this paper
• Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6

  2010cited by this paper
• Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia

  2009cited by this paper
• Clinically Relevant Effects of Convection-Enhanced Delivery of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Aged Rhesus Monkeys

  2009cited by this paper
• Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

  2009cited by this paper
• Single Nigrostriatal Dopaminergic Neurons Form Widely Spread and Highly Dense Axonal Arborizations in the Neostriatum

  2009cited by this paper
• Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain

  2009cited by this paper
• Efficient gene therapy-based method for the delivery of therapeutics to primate cortex

  2009cited by this paper
• Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates.

  2009cited by this paper
• Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

  2008cited by this paper
• GFAP promoter elements required for region‐specific and astrocyte‐specific expression

  2008cited by this paper
• Intraputamenal Infusion of Exogenous Neurturin Protein Restores Motor and Dopaminergic Function in the Globus Pallidus of MPTP-Lesioned Rhesus Monkeys

  2008cited by this paper
• Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum.

  2008cited by this paper
• In vivo reprogramming of adult pancreatic exocrine cells to β-cells

  2008cited by this paper
• Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.

  2008cited by this paper
• Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.

  2007cited by this paper
• Striatal delivery of CERE‐120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys

  2007cited by this paper
• Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.

  2007cited by this paper
• Subthalamic Glutamic Acid Decarboxylase Gene Therapy: Changes in Motor Function and Cortical Metabolism

  2007cited by this paper
• Tissue distribution of Ret, GFRalpha-1, GFRalpha-2 and GFRalpha-3 receptors in the human brainstem at fetal, neonatal and adult age.

  2007cited by this paper
• Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand

  2007cited by this paper
• Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

  2007cited by this paper
• Ras, PI(3)K and mTOR signalling controls tumour cell growth

  2006cited by this paper
• Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease

  2006cited by this paper
• A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys.

  2006cited by this paper
• Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain.

  2006cited by this paper
• Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.

  2006cited by this paper
• Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys

  2006cited by this paper
• Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease

  2005cited by this paper
• Gaucher disease and parkinsonism.

  2005cited by this paper
• Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor.

  2005cited by this paper
• Lentiviral transduction of murine oligodendrocytes in vivo

  2005cited by this paper
• Promoters and control elements: designing expression cassettes for gene therapy.

  2004cited by this paper
• Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease

  2003cited by this paper
• Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area

  2003cited by this paper
• Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.

  2002cited by this paper

• Properties and Application of Pseudotyped Lentiviral Vectors.

  2026cites this paper
• Antioxidant and neuroprotection properties are involved in the anti-Parkinson potential of plumbagin and resveratrol in rotenone-induced Parkinson-like conditions

  2025cites this paper
• Oligodendrocytes, the Forgotten Target of Gene Therapy

  2024cites this paper
• Adeno-Associated Viral Vectors as Versatile Tools for Neurological Disorders: Focus on Delivery Routes and Therapeutic Perspectives

  2022cites this paper
• Recent advances in genetically modified large-animal models of human diseases

  2022influential citation
• Visualizing advances in the future of primate neuroscience research

  2022cites this paper
• Promising drug targets and associated therapeutic interventions in Parkinson’s disease

  2021cites this paper
• Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy.

  2021cites this paper
• Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques

  2021cites this paper
• Adeno-Associated Viral Vectors as Versatile Tools for Parkinson’s Research, Both for Disease Modeling Purposes and for Therapeutic Uses

  2021cites this paper
• Modeling Parkinson’s Disease: Not Only Rodents?

  2021cites this paper
• Light microscopic and heterogeneity analysis of astrocytes in the common marmoset brain

  2021cites this paper
• Pseudotyped lentiviral vectors for tract-targeting and application for the functional control of selective neural circuits.

  2020cites this paper
• Modeling Parkinson’s Disease With the Alpha-Synuclein Protein

  2020cites this paper
• Opportunities and limitations of genetically modified nonhuman primate models for neuroscience research

  2020cites this paper
• Emerging regenerative medicine and tissue engineering strategies for Parkinson’s disease

  2020cites this paper
• Neuroanatomical tract-tracing techniques that did go viral

  2020cites this paper
• Synaptic effects of ethanol on the agranular insunlar cortex

  2019cites this paper
• Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine

  2019cites this paper
• Parkinson disease

  2019cites this paper
• The use of chemogenetic approaches in alcohol use disorder research and treatment.

  2019cites this paper
• Four main therapeutic keys for Parkinson’s disease: A mini review

  2019cites this paper
• Non-human primate research of basal ganglia and movement disorders: advances and challenges

  2018cites this paper
• The use of nonhuman primate models to understand processes in Parkinson’s disease

  2018cites this paper
• Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death

  2018cites this paper